ARTICLE | Clinical News
ONT-380: Phase II started
March 7, 2016 8:00 AM UTC
Oncothyreon began a double-blind, placebo-controlled, international Phase II trial to evaluate 300 mg oral ONT-380 twice daily for 21 days plus Xeloda capecitabine and Herceptin trastuzumab in about...